Secton II: Understanding dyspnoea in COPD: Mechanisms, measurement and management: Introduction

European Respiratory Review

Volumn 12, Issue 82, 2002, Pages

  Mahler, D A ^a  

^a DARTMOUTH HITCHCOCK MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BETA ADRENERGIC RECEPTOR STIMULATING AGENT; BRONCHODILATING AGENT; CHOLINERGIC RECEPTOR BLOCKING AGENT; CORTICOSTEROID; SALBUTAMOL;

BREATHING MUSCLE; BREATHING PATTERN; CHRONIC OBSTRUCTIVE LUNG DISEASE; CORRELATION ANALYSIS; DAILY LIFE ACTIVITY; DIAGNOSTIC PROCEDURE; DYSPNEA; EDITORIAL; FORCED EXPIRATORY VOLUME; HUMAN; INSPIRATORY CAPACITY; LUNG VENTILATION;

EID: 0036701372     PISSN: 09059180     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Editorial

References (87)

1. Meakins JM. Dyspnea. JAMA 1934; 103: 1442-1445.
2. Burki NK. Dyspnea in chronic airways obstruction. Chest 1980; 77: 298-299.
3. Campbell EJM, Guz A. Breathlessness. In: Hornbein T, ed. Regulation of Breathing, Part 2. New York, Marcel Dekker, 1981; pp. 1181-1195.
4. Killian KJ, Jones NL. The use of exercise testing and other methods in the investigation of dyspnea. Clin Chest Med 1984; 5: 99-108.
5. Cockcroft A, Adams L. Measurement and mechanisms of breathlessness. Bull Eur Physiopathol Respir 1986; 22: 85-92.
6. Anonymous. The enigma of breathlessness. Lancet 1986; 1: 891-892.
7. Killian KJ, Jones NL. Respiratory muscles and dyspnea. Clin Chest Med 1988; 9: 237-248.
8. Wasserman K, Casaburi R. Dyspnea: Physiological and pathophysiological mechanisms. Annu Rev Med 1988; 39: 503-515.
9. American Thoracic Society. Dyspnea. Mechanisms, assessment, and management: A consensus statement. Am J Respir Crit Care Med 1999; 159: 321-340.
10. Baird JC, Noma E. Fundamentals of Scaling and Psychophysics. New York, J Wiley & Sons, 1978.
11. Harver A, Mahler DA, Schwartzstein RM, Baird J. Descriptors of breathlessness in healthy individuals. Distinct and separable constructs. Chest 2000; 118: 679-690.
12. Adams L, Guz A. Respiratory sensation. In: Adams L, Guz A, eds. Lung Biology in Health and Disease. Vol. 90. New York, Marcel Dekker, 1996; p. 416.
13. Campbell E. A thoughtful being breathing thoughtful breaths. Am J Respir Crit Care Med 2000; 162: 2027-2028.
14. Mahler DA, Harver A. A factor analysis of dyspnea ratings, respiratory muscle strength, and lung function in patients with chronic obstructive pulmonary disease. Am Rev Respir Dis 1992; 145: 467-470.
15. Cott A. The disease-illness distinction: A model for effective and practical integration of behavioural and medical sciences. In: McHugh S, Vallis T; eds. Illness Behavior: A Multidisciplinary Model. New York, Plenum Press, 1986; pp. 71-99.
16. Dubuisson D, Melzack R. Classification of clinical pain descriptions by multiple group discriminate analysis. Exp Neurol 1976; 51: 480-487.
17. Hunter M, Phillips C. The experience of headache - An assessment of the qualities of tension headache pain. Pain 1981; 10: 209-219.
18. Simon PM, Schwartzstein RM, Weiss JW, et al. Distinguishable sensations of breathlessness induced in normal volunteers. Am Rev Respir Dis 1989; 140: 1021-1027.
19. Simon PM, Schwartzstein RM, Weiss JW, Fencl V, Teghtsoonian M, Weinberger SE. Distinguishable types of dyspnea in patients with shortness of breath. Am Rev Respir Dis 1990; 142: 1009-1014.
20. Elliott MW, Adams L, Cockcroft A, MacRae KD, Murphy K, Guz A. The language of breathlessness. Use of verbal descriptors by patients with cardiopulmonary disease. Am Rev Respir Dis 1991; 144: 826-832.
21. Mahler DA, Harver A, Lentine T, Scott JA, Beck K, Schwartzstein RM. Descriptors of breathlessness in cardiorespiratory diseases. Am J Respir Crit Care Med 1996; 154: 1357-1363.
22. Skevington SM, Pilaar M, Routh D, Macleod RD. On the language of breathlessness. Psychol Health 1997; 12: 677-689.
23. Hardie GE, Janson S, Gold WM, Carrieri-Kohlman V, Boushey HA. Ethnic differences: Word descriptors used by African-American and white asthma patients during induced bronchoconstriction. Chest 2000; 117: 935-943.
24. O'Donnell DE, Sanii R, Giesbrecht G, Younes M. Effect of continuous positive airway pressure on respiratory sensation in patients with chronic obstructive pulmonary disease during submaximal exercise. Am Rev Respir Dis 1988; 138: 1185-1191.
25. O'Donnell DE, Webb KA. Exertional breathlessness in patients with chronic airflow limitation. The role of lung hyperinflation. Am Rev Respir Dis 1993; 148: 1351-1357.
26. O'Donnell DE, Lam MIU, Webb KA. Measurement of symptoms, lung hyperiflation, and endurance during exercise in chronic obstructive pulmonary disease. Am J Respir Crit Care Med 1998; 158: 1557-1565.
27. Marin JM, Montes de Oca M, Rassulo J, Celli BR. Ventilatory drive at rest and perception of exertional dyspnea in severe COPD. Chest 1999; 115: 1293-1300.
28. O'Donnell DE, Bertley JC, Chau LK, Webb KA. Qualitative aspects of exertional breathlessness in chronic airflow limitation: Pathophysiologic mechanisms. Am J Respir Crit Care Med 1997; 155: 109-115.
29. Binks AP, Moosavi SH, Banzett RB, Schwartzstein RM. "Tightness" sensation of asthma does not arise from the work of breathing. Am J Respir Crit Care Med 2002; 165: 78-82.
30. Killian KJ, Watson R, Otis J, St Amand TA, O'Byrne PM. Symptom perception during acute bronchoconstriction. Am J Respir Crit Care Med 2000; 162: 490-496.
31. Moy ML, Woodrow Weiss J, Sparrow D, Israel E, Schwartzstein RM. Quality of dyspnea in bronchoconstriction differs from external resistive loads. Am J Respir Crit Care Med 2000; 162: 451-455.
32. Moy ML, Lantin ML, Harver A, Schwartzstein RM. Language of dyspnea in assessment of patients with acute asthma treated with nebulized albuterol. Am J Respir Crit Care Med 1998; 158: 749-753.
33. Taguchi O, Kikuchi Y, Hida W, et al. Effects of bronchoconstriction and external resistive loading on the sensation of dyspnea. J Appl Physiol 1991; 71: 2183-2190.
34. Pratter MR, Curley FJ, Dubois J, Irwin RS. Cause and evaluation of chronic dyspnea in a pulmonary disease clinic. Arch Intern Med 1989; 149: 2277-2282.
35. Harver A, Mahler DA, Schwartzstein RM. Use of a descriptor model for prospective diagnosis of chronic dyspnea. Am J Respir Crit Care Med 2000; 161: A705.
36. Stevens SS. On the theory of scales of measurement. Science 1946; 103: 677-680.
37. Fletcher CM, Elmes PC, Fairbain AS. The significance of respiratory symptoms and diagnosis of chronic bronchitis in working population. BMJ 1959; 2: 257-266.
38. Mahler DA, Weinberg DH, Wells CK, Feinstein AR. The measurement of dyspnea. Contents, interobserver agreement, and physiologic correlates of two new clinical indexes. Chest 1984; 85: 751-758.
39. Mahler DA, Tomlinson D, Olmstead EM, Tosteson ANA, O'Connor GT. Changes in dyspnea, health status, and lung function in chronic airway disease. Am J Respir Crit Care Med 1995; 151: 61-65.
40. Guyatt GH, Berman LB, Townsend M, Pugsley SO, Chambers LW. A measure of quality of life for clinical trials in chronic lung disease. Thorax 1987; 42: 773-778.
41. Eakin EG, Resnikoff PM, Prewitt LM, Ries AL, Kaplan RM. Validation of a new dyspnea measure: The UCSD Shortness of Breath Questionnaire. University of California, San Diego. Chest 1998; 113: 619-624.
42. Lareau SC, Meek PM, Roos PJ. Development and testing of the modified version of the Pulmonary Functional Status and Dyspnea Questionnaire (PFSDQ-M). Heart Lung 1998, 27: 159-168.
43. Borg G, Holmgren A, Lindblad I. Quantitative evaluation of chest pain. Acta Med Scand Suppl 1981; 644: 43-45.
44. Killian KJ, Leblanc P, Martin DH, Summers E, Jones NL, Campbell EJ. Exercise capacity and ventilatory, circulatory, and symptom limitation in patients with chronic airflow limitation. Am Rev Respir Dis 1992; 146: 935-940.
45. Hamilton AL, Killian KJ, Summers E, Jones NL. Symptom intensity and subjective limitation to exercise in patients with cardiorespiratory disorders. Chest 1996; 110: 255-1263.
46. Franco MJ, Olmstead EM, Tosteson ANA, Lentine T, Ward J, Mahler DA. Comparison of dyspnea ratings during submaximal constant work exercise with incremental testing. Med Sci Sports Exerc 1998; 30: 479-482.
47. Stevens S, Galanter E. Ratio scales and category scales for a dozen perceptual continua. J Exp Psychol 1957; 54: 377-411.
48. Stevens SS, ed. Psychophysics. Introduction to Its Perceptual, Neural, and Social Prospects, New York, John Wiley & Sons, 1975.
49. Killian KJ, Robers JA, Jones NL, Summers E. How reliable is self perception of exercise capacity in patients with cardiopulmonary disease? Am J Respir Crit Care Med 1997; 155: A168.
50. O'Donnell DE, D'Arsigny C, Webb KA. Effects of hyperoxia on ventilatory limitation during exercise in advanced chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2001; 163: 892-898.
51. O'Donnell DE, Revill S, Webb KA. Dynamic hyperinflation during exercise in COPD: Physiological correlates. Am J Respir Crit Care Med 2001; 163: A269.
52. Diaz O, Villafranca C, Ghezzo H, et al. Role of inspiratory capacity on exercise tolerance in COPD patients with and without tidal expiratory flow limitation at rest. Eur Respir J 2000; 16: 269-275.
53. O'Donnell DE, Bain DJ, Webb KA. Factors contributing to relief of exertional breathlessness during hyperoxia in chronic airflow limitation. Am J Respir Crit Care Med 1997; 155: 530-535.
54. O'Donnell DE, Hong HH, Webb KA. Respiratory sensation during chest wall restriction and dead space loading in exercising men. J Appl Physiol 2000; 88: 1859-1869.
55. Tantucci C, Duguet A, Similowski T, Zelter M, Derenne JP, Milic-Emili J. Effect of salbutamol on dynamic hyperinflation in chronic obstructive pulmonary disease patients. Eur Respir J 1998; 12: 799-804.
56. American Thoracic Society. Standards for the diagnosis and care of patients with chronic obstructive pulmonary disease (COPD). Am J Respir Crit Care Med 1995; 152: S77-S120.
57. Siafakas NM, Vermeire P, Pride NB, et al. Optimal assessment and management of chronic obstructive pulmonary disease (COPD). Eur Respir J 1995; 8: 1398-1420.
58. O'Donnell DE, Forkert L, Webb KA. Evaluation of bronchodilator responses in patients with "irreversible" emphysema. Eur Respir J 2001; 18: 914-920.
59. O'Donnell DE, Lam MIU, Webb KA. Spirometric correlates of improvement in exercise performance after anticholinergic therapy in chronic obstructive pulmonary disease. Am J Respir Crit Care Med 1999; 160: 542-549.
60. Belman MJ, Botnick WC, Shin JW. Inhaled bronchodilators reduce dynamic hyperinflation during exercise in patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med 1996; 153: 967-975.
61. Taube C, Lehnigk B, Paasch K, Kirsten DK, Jorres RA, Magnussen H. Factor analysis of changes in dyspnea and lung function parameters after bronchodilation in chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2000; 162: 216-220.
62. Casaburi R, Mahler DA, Jones PW, et al. A long-term evaluation of once-daily inhaled tiotropium in chronic obstructive pulmonary disease. Eur Respir J 2002; 19: 217-224.
63. Vincken W, van Noord JA, Greefhorst APM, et al. Improved health outcomes in patients with COPD during 1 yr's treatment with tiotropium. Eur Respir J 2002; 19: 209-216.
64. Harver A, Mahler DA, Daubenspeck JA. Targeted inspiratory muscle training improves respiratory muscle function and reduces dyspnea in patients with chronic obstructive pulmonary disease. Ann Intern Med 1989; 111: 117-124.
65. Lisboa C, Villafranca C, Leiva A, Cruz E, Pertuze J, Borzone G. Inspiratory muscle training in chronic airflow limitation: Effect on exercise performance. Eur Respir J 1997; 10: 537-542.
66. Martinez FJ, de Oca MM, Whyte RI, Stetz J, Gay SE, Celli BR. Lung-volume reduction improves dyspnea, dynamic hyperinflation, and respiratory muscle function. Am J Respir Crit Care Med 1997; 155: 1984-1990.
67. Mahler DA, Wells CK. Evaluation of clinical methods for rating dyspnea. Chest 1988; 93: 580-586.
68. Tsukino M, Nishimura K, Ikeda A, Koyama H, Mishima M, Izumi T. Physiologic factors that determine the health-related quality of life in patients with COPD. Chest 1996; 110: 896-903.
69. Redelmeier D, Guyatt G, Goldstein R. Assessing the minimal important difference in symptoms: A comparison of two techniques. J Clin Epidemiol 1996; 49: 1215-1219.
70. Witek TJ, Mahler DA. Meaningful effect size and patterns of response of the Transition Dyspnoea Index. J Clin Epidemiol 2002 (in press).
71. Guyatt GH, Townsend M, Pugsley SO, et al. Bronchodilators in chronic air-flow limitation. Effects on airway function, exercise capacity, and quality of life. Am Rev Respir Dis 1987; 135: 1069-1074.
72. Mahler DA, Matthay RA, Snyder PE, Wells CK, Loke J. Sustained-release theophylline reduces dyspnea in nonreversible obstructive airway disease. Am Rev Respir Dis 1985; 131: 22-25.
73. McKay SE, Howie CA, Thomson AH, Whiting B, Addis GJ. Value of theophylline treatment in patients handicapped by chronic obstructive lung disease. Thorax 1993; 48: 227-232.
74. Wise R, Connett JE, Weinmann G, Scanlon P, Skeans M. Effect of inhaled triamcinolone on the decline in pulmonary function in chronic obstructive pulmonary disease. N Engl J Med 2000; 343: 1902-1909.
75. Mahler DA, Donohue JF, Barbee RA, et al. Efficacy of salmeterol xinafoate in the treatment of COPD. Chest 1999; 115: 957-965.
76. Ries AL, Kaplan RM, Limberg TM, Prewitt LM. Effects of pulmonary rehabilitation on physiologic and psychosocial outcomes in patients with chronic obstructive pulmonary disease. Ann Intern Med 1995; 122: 823-832.
77. O'Donnell DE, McGuire M, Samis L, Webb KA. The impact of exercise reconditioning on breathlessness in severe chronic airflow limitation. Am J Respir Crit Care Med 1995; 152: 2005-2013.
78. Goldstein RS, Gort EH, Stubbing D, Avendano MA, Guyatt GH. Randomised controlled trial of respiratory rehabilitation. Lancet 1994; 344: 1394-1397.
79. Reardon J, Awad E, Normandin E, Vale F, Clark B, ZuWallack RL. The effect of comprehensive outpatient pulmonary rehabilitation on dyspnea. Chest 1994; 105: 1046-1052.
80. Geddes D, Davies M, Koyama H, et al. Effect of lung-volume-reduction surgery in patients with severe emphysema. N Engl J Med 2000; 343: 239-245.
81. Sibuya M, Yamada M, Kanamaru A, et al. Effect of chest wall vibration on dyspnea in patients with chronic respiratory disease. Am J Respir Crit Care Med 1994; 149: 1235-1240.
82. Smith K, Cook D, Guyatt GH, Madhavan J, Oxman AD. Respiratory muscle training in chronic airflow limitation: A meta-analysis. Am Rev Respir Dis 1992; 145: 533-539.
83. Efthimiou J, Fleming J, Gomes C, Spiro SG. The effect of supplementary oral nutrition in poorly nourished patients with chronic obstructive pulmonary disease. Am Rev Respir Dis 1988; 137: 1075-1082.
84. Borson S, McDonald GJ, Gayle T, Deffebach M, Lakshminarayan S, VanTuinen C. Improvement in mood, physical symptoms, and function with nortriptyline for depression in patients with chronic obstructive pulmonary disease. Psychosomatics 1992; 33: 190-201.
85. Wilson RC, Jones PW. Influence of prior ventilatory experience on the estimation of breathlessness during exercise. Clin Sci 1990; 78: 149-153.
86. Guyatt GH, Thompson PJ, Berman LB, et al. How should we measure function in patients with chronic heart and lung disease? J Chronic Dis 1985; 38: 517-524.
87. Cazzola M, Santangelo G, Piccolo A, et al. Effect of salmeterol and formoterol in patients with chronic obstructive pulmonary disease. Pulm Pharmacol 1994; 7: 103-107.